Shares of ResMed Inc. RMD rose 1.67% to $254.70 Monday, on what proved to be an all-around mixed trading session for the ...

Veeva Systems Inc. VEEV, on Thursday, announced a product partnership with Zifo. The tie-up aims to help biopharmas modernize ...

The market expects BellRing Brands (BRBR) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...

In a report released on January 24, David Low from J.P. Morgan maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of ...

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story ...

It’s shaping up as a big year for late-stage Australian-listed drug developers, with analysts tipping potentially hefty share ...

The digital therapeutics market size was valued at $3,845.74 Million in 2021, and is projected to reach $22,601.97 Million by 2031, registering a CAGR of 19.4%.

Pacer US Cash Cows Growth ETF combines value and growth, but performance lags. Read why BUL’s record since inception isn’t as ...

ResMed’s stock has surged but faces potential risks from GLP-1 drugs. Find out why RMD stock remains a Hold as investors ...

Find insight on Johnson & Johnson, Novo Nordisk and more in the latest Market Talks covering Health Care.

Taking all of the above, and more, into account, Morgans' key calls for February include Computershare, Guzman y Gomez, Lovisa Holdings, Megaport, Pinnacle Investment Management and Superloop.

If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to ...